View Older Stories View More Recent Stories

Jan 28, 2016 06:59PM Merck Receives FDA Approval of ZEPATIER™ (elbasvir and grazoprevir) for the Treatment of Chronic Hepatitis C Virus Genotype 1 or 4 Infection in Adults Following Priority Review
Jan 27, 2016 08:31AM Merck (MRK) Announces FDA Acceptance of Bezlotoxumab BLA in C. difficile Prevention
Jan 27, 2016 08:30AM Merck Announces FDA Acceptance of Biologics License Application for Bezlotoxumab, an Investigational Antitoxin for Prevention of Clostridium Difficile Infection Recurrence
Jan 25, 2016 09:32AM Pre-Open Stock Movers 01/25: (AFMD) (GRUB) (SUNE) (TYC) Higher; (OMED) (NVAX) (TWTR) Lower (more...)
Jan 19, 2016 10:00AM Data for KEYTRUDA® (pembrolizumab) in a Range of Gastrointestinal Cancers to be Presented at 2016 Gastrointestinal Cancers Symposium
Jan 15, 2016 07:00AM Merck (MRK) Announces Resolation to Vioxx Securities Class Action; Will Pay $830M
Jan 15, 2016 07:00AM Merck Resolves Previously Disclosed Securities Class Action Lawsuit Related to Vioxx
Jan 11, 2016 04:08PM Merck (MRK) Announces Acquisition of IOmet
Jan 11, 2016 04:08PM Merck Acquires IOmet Pharma and Expands Immuno-Oncology Development Program
Jan 8, 2016 08:00AM Merck to Present at the 34th Annual J.P. Morgan Healthcare Conference
Jan 5, 2016 08:00AM Merck to Hold Fourth-Quarter and Full-Year 2015 Sales and Earnings Conference Call on February 3
Jan 4, 2016 08:00AM Merck to Present at Goldman Sachs Healthcare CEOs Unscripted: A View from the Top
Dec 23, 2015 08:34AM Merck (MRK) Announces WHO Acceptance of EUAL for Ebola Zaire Vaccine
Dec 23, 2015 08:30AM World Health Organization to Review Merck’s Investigational Ebola Vaccine for Emergency Use Assessment and Listing
Dec 19, 2015 10:55AM Merck’s KEYTRUDA® (pembrolizumab) Significantly Improves Survival Compared to Chemotherapy in Previously-Treated Patients with Non-Small Cell Lung Cancer Whose Tumors Express Any Level of PD-L1
Dec 18, 2015 04:06PM Merck (MRK) Announces Expanded Indication for KEYTRUDA
Dec 18, 2015 04:05PM FDA Approves Expanded Indication for Merck’s KEYTRUDA® (pembrolizumab) for the Treatment of Patients with Advanced Melanoma
Dec 18, 2015 08:04AM Merck's (MRK) Elbasvir/Grazoprevir MAA Will New Come Under EMA CHMP Standard Review
Dec 18, 2015 08:00AM Merck Provides Update on European Medicines Agency Marketing Authorization Application for Investigational Chronic Hepatitis C Therapy Elbasvir/Grazoprevir
Dec 15, 2015 05:09PM Merck (MRK) Says GARDASIL 9 Age Expanded in Males 16-26
Dec 15, 2015 05:07PM FDA Approves Expanded Age Indication for GARDASIL® 9 in Males
Dec 10, 2015 09:00AM Biothera Announces Clinical Study to Evaluate Combination Therapy of Imprime PGG and Merck's Checkpoint Inhibitor Keytruda in Patients with Non-Small Cell Lung Cancer
Dec 10, 2015 06:31AM Eli Lilly & Co. (LLY), Merck (MRK) Enter Collaboration for Abemaciclib Phase 1
Dec 10, 2015 06:30AM Lilly and Merck Expand Immuno-Oncology Collaboration Adding Abemaciclib and KEYTRUDA® Combination Trial
Dec 8, 2015 08:06AM Merck (MRK) Presents KEYTRUDA Data at ASH 2015
Dec 8, 2015 08:00AM Findings Across a Range of Hematological Cancers Add to The Growing Breadth of KEYTRUDA® (pembrolizumab) Data
Dec 7, 2015 08:03AM Merck (MRK) Announces Receipt of RENFLEXIS Approval in Korea
Dec 7, 2015 08:00AM Merck Announces Samsung Bioepis Receives Approval of RENFLEXIS™ (Infliximab), a Biosimilar of Remicade, in Korea
Dec 7, 2015 07:00AM Responses Observed in Three-Quarters of Heavily Pre-Treated Multiple Myeloma Patients Receiving KEYTRUDA® (pembrolizumab) Combined With Lenalidomide and Dexamethasone
Dec 4, 2015 08:01AM Amgen And Merck Announce Cancer Immunotherapy Collaboration For Patients With Non-Hodgkin Lymphoma
Nov 30, 2015 08:30AM New Survey Showed That Most People Living With HIV Were More Concerned About Their Other Chronic Health Conditions Than Their HIV
Nov 24, 2015 12:35PM Merck Announces Increased Quarterly Dividend
Nov 21, 2015 04:30PM Merck Announces Initial Results for KEYTRUDA® (pembrolizumab) with Novel Immunotherapy Combinations from Three Investigational Studies Presented at the Society for Melanoma Research International Con
Nov 19, 2015 06:30AM Lilly and Merck Expand Immuno-oncology Collaboration with Phase III Nonsquamous Non-Small Cell Lung Cancer Trial
Nov 17, 2015 08:00AM New Studies Investigating the Use of KEYTRUDA® (pembrolizumab) Across Solid and Hematological Cancers to Be Presented at Upcoming Congresses
Nov 16, 2015 08:30AM Merck Announces Presentation of Results from Two Phase 2 Studies of Investigational Triple-Combination Chronic Hepatitis C Therapy at The Liver Meeting®
Nov 14, 2015 07:00PM Merck to Release Findings from Integrated Analysis of Six Phase 2 and 3 Clinical Trials Evaluating Investigational Elbasvir/Grazoprevir in Patients with Chronic Hepatitis C Genotype 1, 4 or 6 Infectio
Nov 14, 2015 07:00PM Merck Announces Presentation of Phase 3 Results of Investigational Elbasvir/Grazoprevir in People with Chronic Hepatitis C Genotypes 1, 4 or 6 Infection Who Inject Drugs and Are on Opioid Agonist Ther
Nov 13, 2015 08:00AM Merck Provides Update on REVEAL Outcomes Study
Nov 12, 2015 05:00PM Merck Animal Health to Acquire Harrisvaccines
Nov 12, 2015 11:49AM Merck Statement Regarding CUBICIN® (daptomycin for injection) Patent Litigation
Nov 6, 2015 02:13PM Merck Statement on FDA Advisory Committee Meeting for BRIDION® (sugammadex), Investigational Agent for the Reversal of Neuromuscular Blockade (NMB) Induced by Rocuronium or Vecuronium
Nov 6, 2015 09:31AM Data on Vericiguat, Investigational Heart Failure Medicine, to be Presented as Late-Breaking Clinical Trial at the 2015 American Heart Association (AHA) Scientific Sessions
Nov 5, 2015 08:43AM Merck Announces Samsung Bioepis Will Present New Biosimilars Data at the 2015 ACR/ARHP Annual Meeting
Nov 3, 2015 06:58AM GSK and Merck to Study Immunotherapy Combination as Potential Cancer Treatment
Nov 2, 2015 08:00AM Merck Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for KEYTRUDA® (pembrolizumab) in Advanced Colorectal Cancer
Oct 28, 2015 08:00AM KEYTRUDA® (pembrolizumab) from Merck Awarded Prix Galien USA 2015 Best Biotechnology Product Award
Oct 27, 2015 05:36PM Market Wrap: Suprise Dip in Confidence for Oct.; Apple Gains on iPhone Sales; Walgreens Boots Moves to Acquire Peer
Oct 27, 2015 07:15AM Wall St. slips on rate uncertainty; Apple up after the bell
Oct 27, 2015 06:45AM Merck Announces Third-Quarter 2015 Financial Results
View More Recent Stories View Older Stories